Evidence map›Paper›PMID 42277225›Full record

ArticleNature biotechnology2026

Large-scale, spatially resolved panoramic CRISPR screening in native tissue environments using Perturb-DBiT.

Alev Baysoy, Xiaolong Tian, Paul Renauer, Feifei Zhang, Zhiliang Bai, Hao Shi, Mingyu Yang, Dingyao Zhang, Miao Liu, Haikuo Li and 25 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Spatial Glyco-Codes Define Human Liver Pathology and Progression.bioRxiv : the preprint server for biology · 2026
    Article
  4. Review
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

35 authors.

Alev Baysoy *Department of Biomedical Engineering, Yale University, New Haven, CT, USA.
Xiaolong Tian *Department of Biomedical Engineering, Yale University, New Haven, CT, USA.
Paul Renauer *Department of Genetics, Yale University School of Medicine, New Haven, CT, USA.
Feifei Zhang *Department of Genetics, Yale University School of Medicine, New Haven, CT, USA.
Zhiliang BaiDepartment of Biomedical Engineering, Yale University, New Haven, CT, USA.ORCID http://orcid.org/0000-0002-3977-3057
Hao ShiDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID http://orcid.org/0000-0002-2796-629X
Mingyu YangDepartment of Biomedical Engineering, Yale University, New Haven, CT, USA.ORCID http://orcid.org/0000-0003-0986-3825
Dingyao ZhangDepartment of Genetics, Yale University School of Medicine, New Haven, CT, USA.
Miao LiuDepartment of Biomedical Engineering, Yale University, New Haven, CT, USA.ORCID http://orcid.org/0000-0003-4248-2661
Haikuo LiDepartment of Biomedical Engineering, Yale University, New Haven, CT, USA.ORCID http://orcid.org/0000-0003-3697-5662
Bo TaoDepartment of Biomedical Engineering, Yale University, New Haven, CT, USA.ORCID http://orcid.org/0000-0002-5490-4668
Archibald EnninfulDepartment of Biomedical Engineering, Yale University, New Haven, CT, USA.
Yao LuDepartment of Biomedical Engineering, Yale University, New Haven, CT, USA.
Fu GaoDepartment of Biomedical Engineering, Yale University, New Haven, CT, USA.
Guangchuan WangDepartment of Genetics, Yale University School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0001-5315-1599
Wanqiu ZhangAspect Analytics, Genk, Belgium.
Thao TranAspect Analytics, Genk, Belgium.
Nathan Heath PattersonAspect Analytics, Genk, Belgium.
Jie ShengDepartment of Biostatistics and Medical Informatics, University of Wisconsin, Madison, WI, USA.ORCID http://orcid.org/0009-0006-0398-5089
Shuozhen BaoDepartment of Biomedical Engineering, Yale University, New Haven, CT, USA.
Chuanpeng DongDepartment of Genetics, Yale University School of Medicine, New Haven, CT, USA.
Shan XinDepartment of Genetics, Yale University School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0002-4735-0935
Binfan ChenDepartment of Genetics, Yale University School of Medicine, New Haven, CT, USA.
Mei ZhongDepartment of Biomedical Engineering, Yale University, New Haven, CT, USA.ORCID http://orcid.org/0000-0003-1230-0775
Sherri RankinDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Cliff GuyDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Yan WangDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Jon P ConnellyCenter for Advanced Genome Engineering, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID http://orcid.org/0000-0002-5564-1775
Shondra M Pruett-MillerCenter for Advanced Genome Engineering, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID http://orcid.org/0000-0002-3793-585X
Daifeng WangDepartment of Biostatistics and Medical Informatics, University of Wisconsin, Madison, WI, USA.ORCID http://orcid.org/0000-0001-9190-3704
Mina XuDepartment of Pathology, Yale University School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0001-9513-245X
Mark B GersteinDepartment of Genetics, Yale University School of Medicine, New Haven, CT, USA.
Hongbo ChiDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID http://orcid.org/0000-0002-9997-2496
Sidi ChenDepartment of Genetics, Yale University School of Medicine, New Haven, CT, USA. sidi.chen@yale.edu.ORCID http://orcid.org/0000-0002-3819-5005
Rong FanDepartment of Biomedical Engineering, Yale University, New Haven, CT, USA. rong.fan@yale.edu.ORCID http://orcid.org/0000-0001-7805-8059

Funding

Spatiotemporal Tumor Analytics for Guiding Sequential Targeted-Inhibitor: Immunotherapy Combinations (ST-Analytics)U54CA274509 · NCI · INSTITUTE FOR SYSTEMS BIOLOGY · PI Rong Fan · 2022 to 2026
$15.6M
Tech Core 2U54CA268083 · NCI · JOHNS HOPKINS UNIVERSITY · PI Pei-Hsun wu · 2022 to 2026
$10.2M
Yale TMC for Cellular Senescence in Lymphoid OrgansU54AG076043 · NIA · YALE UNIVERSITY · PI FAN, RONG, HALENE, STEPHANIE · 2021 to 2025
$7.0M
Yale Murine-TMC on Immune Cell Senescence Derived InflammationU54AG079759 · NIA · YALE UNIVERSITY · PI DIXIT, VISHWA DEEP, MONTGOMERY, RUTH R · 2022 to 2025
$6.5M
High-throughput in vivo and in vitro functional and multi-omics screens of neuropsychiatric and neurodevelopmental disorder risk genesRM1MH132648 · NIMH · YALE UNIVERSITY · PI Kristen Jennifer Brennand, Rong Fan · 2023 to 2026
$5.6M
Center for Human Lymphoma Spatiotemporal Atlas (HuLymSTA)U01CA294514 · NCI · YALE UNIVERSITY · PI FAN, RONG, HALENE, STEPHANIE · 2024 to 2025
$5.1M
Highly scalable and sensitive spatial transcriptomic and epigenomic sequencing of brain tissues from human and non-human primateRF1MH128876 · NIMH · YALE UNIVERSITY · PI FAN, RONG, SESTAN, NENAD · 2021 to 2021
$2.9M
Ex vivo analysis of human brain tumor cells in a microvascular niche modelR01CA245313 · NCI · YALE UNIVERSITY · PI FAN, RONG, ZHOU, JIANGBING · 2020 to 2024
$2.6M
Advanced development of composite gene delivery and CAR engineering systemsR33CA281702 · NCI · YALE UNIVERSITY · PI CHEN, SIDI · 2023 to 2025
$1.2M
High-spatial-resolution ECM-inclusive multi-omics sequencing of human PFA and FFPE tissue slidesUH3CA257393 · NCI · YALE UNIVERSITY · PI FAN, RONG · 2022 to 2023
$1.2M
Cancer Research Institute (CRI) CRI4964U.S. Department of Defense (United States Department of Defense) HT94252310472U.S. Department of Health & Human Services | National Institutes of Health (NIH) RF1MH128876U.S. Department of Health & Human Services | National Institutes of Health (NIH) RM1MH132648U.S. Department of Health & Human Services | National Institutes of Health (NIH) U54AG076043U.S. Department of Health & Human Services | National Institutes of Health (NIH) U54AG079759U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA245313U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R33CA281702U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) U01CA294514U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) U54CA268083U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) U54CA274509U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) UH3CA257393
6 · The paper itself

Abstract

Spatially resolved CRISPR screening in vivo has been limited to small perturbation panels and subsets of protein-coding RNAs. We present Perturb-DBiT, a method for co-sequencing of spatial total RNA whole transcriptomes and single guide RNAs (sgRNAs) on the same tissue section in situ. In a human cancer metastatic colonization model, we applied large (80,000+) sgRNA panels across tumor colonies in multiple consecutive tissue sections alongside their corresponding total RNA transcriptomes. We linked perturbations affecting long noncoding RNA covariation, microRNA-mRNA interactions and distinct amino acid-specific tRNA alterations to tumor migration and growth. By integrating transcriptional pseudotime trajectories, we further observed the impact of perturbations on clonal dynamics and cooperation. In an immune-competent syngeneic mouse model, investigation of the tumor immune microenvironment indicated distinct, synergistic effects on immune infiltration and suppression. Perturb-DBiT provides a spatially resolved comprehensive view of perturbation responses in complex tissues, including small and large RNA regulation, tumor proliferation, migration, metastasis and immune interactions.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.